Cite
HARVARD Citation
Schiffmann, R. et al. (2019). Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial. Journal of inherited metabolic disease. 42 (3), pp. 534-544. [Online].